{"id":"W4397007301","doi":"10.1016/j.esmoop.2024.103220","title":"198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Japanese Society of Medical Oncology; Daewoong Pharmaceutical Company; Chugai Pharmaceutical; Seagen; Radius Health; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Immunotherapy; Cancer; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009129281,0.0004627315,0.001020794,0.0002033806,0.0001857213,0.0006061612,0.0004522035,0.0005972807,0.004753553],"category_scores_gemma":[0.0007219108,0.0002617033,0.001008196,0.0002061157,0.000369247,0.0005346977,0.0003320979,0.002092157,0.0006097023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007750586,"about_ca_system_score_gemma":0.0008904451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00091472,"about_ca_topic_score_gemma":0.00254541,"domain_scores_codex":[0.9996539,0.0001689578,0.00002592344,0.00005415889,0.00003717532,0.00005980544],"domain_scores_gemma":[0.9995688,0.0001065558,0.0001246073,0.00002373846,0.00001771283,0.0001585421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.9294982,0.01035099,0.00197075,0.0005234121,0.0007885411,0.00005211884,0.00004060234,0.0008156237,0.01037573,0.0001676345,0.002076534,0.04333983],"study_design_scores_gemma":[0.5804258,0.3924124,0.0178533,0.00009889846,0.001287677,0.0001507523,0.00005471811,0.001964458,0.002676515,0.0002993972,0.002750578,0.0000255355],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918087,0.00246285,0.0002819182,0.0004801654,0.0002591654,0.0009791777,0.001429864,0.00003428789,0.002263869],"genre_scores_gemma":[0.9940758,0.0009511865,0.0004788395,0.0005112053,0.0001208285,0.0008983188,0.00113667,0.000009244809,0.001817849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004753553,"threshold_uncertainty_score":0.01590222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04492359654625794,"score_gpt":0.335588798989936,"score_spread":0.2906652024436781,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}